Beyond Meat Inc is a pioneering company in the food industry that specializes in producing plant-based meat substitutes designed to replicate the taste and texture of traditional meat products. Their innovative offerings cater to consumers looking for alternatives that align with healthier lifestyles and sustainable practices, addressing concerns around environmental impact, animal welfare, and personal health. Beyond Meat develops a range of products, including burgers, sausages, and ground meat, which are available in grocery stores, restaurants, and foodservice operations, aiming to provide a delicious and satisfying experience for both meat-eaters and those reducing their meat consumption. Read More
Plant-based protein company Beyond Meat (NASDAQ:BYND) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 15.3% year on year to $58.21...
EL SEGUNDO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ: BYND), otherwise known as Beyond The Plant Protein CompanyTM (the “Company” or “Beyond Meat”), today reported financial results for its first quarter ended March 28, 2026.
Plant-based protein company Beyond Meat (NASDAQ:BYND) will be announcing earnings results this Wednesday after market hours. Here’s what investors should kno...
Beyond Meat Inc. shares surged in after-hours trading, rising 4.80% to $1.03 after a sharp 20.70% intraday rally, as investors positioned ahead of the company's May 6 earnings release amid ongoing volatility near its 52-week low.
EL SEGUNDO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ: BYND), otherwise known as Beyond The Plant Protein Company™ (the “Company”), today announced it will report financial results for its first quarter ended March 28, 2026 on Wednesday, May 6, 2026 after market close.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
The oral thin film drug delivery market is entering a high-growth phase, with industry forecasts projecting expansion from $3.30 billion in 2025 to $5.21 billion by 2030, representing a 9.56% CAGR . As demand accelerates for faster, more efficient drug delivery systems , companies positioned at the forefront of this innovation—such as Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF)—are increasingly drawing investor attention.
